"A safe and effective vaccine against COVID-19 is urgently needed in quantities sufficient to immunise large populations. We report the preclinical development of two BNT162b vaccine candidates, which contain lipid-nanoparticle (LNP) formulated nucleoside-modified mRNA encoding SARS-CoV-2 spike glycoprotein-derived immunogens. BNT162b1 encodes a soluble, secreted, trimerised receptor-binding domain (RBD-foldon). BNT162b2 encodes the full-length transmembrane spike glycoprotein, locked in its prefusion conformation (P2 S). The flexibly tethered RBDs of the RBD-foldon bind ACE2 with high avidity. Approximately 20% of the P 2S trimers are in the two-RBD ‘down,’ one-RBD ‘up’ state. "
https://www.nature.com/articles/s41586-021-03275-y?utm_source=sn&utm_medium=referral&utm_content=RMarketing&utm_campaign=BSLB_1_CA01_BSLB_AWA_CA01_GL_LSGR_PubH_Coronavirus_LandingPage
Coronavirus Cases:
108.355 million
Deaths:
2.380 million
Recovered:
80.406 million
Yes! Please see the following link.
https://www.news-medical.net/amp/news/20210211/New-study-shares-preliminary-data-on-Pfizer-vaccinee28099s-effectiveness-in-Israel.aspx
Yes! Please see the following link.
https://www.news-medical.net/amp/news/20210211/New-study-shares-preliminary-data-on-Pfizer-vaccinee28099s-effectiveness-in-Israel.aspx
Please also have a look at this link.
https://www.news-medical.net/amp/news/20210208/Research-from-Israel-shows-mRNA-vaccine-is-7e5025-effective-in-reducing-severe-cases.aspx
Dear Ijaz Durrani yes! In addition to the useful links provided by Arvind Singh please also see this relevant article entitled
"BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans"
https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1.full
It is a preprint which has not yet been peer-reviewed.
Dear Ijaz Durrani most other recent articles on this topic describes the results of studies with non-human primates, e.g.
1. BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2
https://www.biorxiv.org/content/10.1101/2020.12.11.421008v1
2. Immunogenic BNT162b vaccines protect rhesus macaques from SARS-CoV-2
https://www.nature.com/articles/s41586-021-03275-y
Kindly take a look at the following useful links:
https://www.nature.com/subjects/virology/nature
Article Immunogenic BNT162b vaccines protect rhesus macaques from SARS-CoV-2
Dear Ijaz Durrani please also see this important link entitled
"Doctors warn that Covid will become endemic and people need to learn to live with it"
https://www.cnbc.com/2021/02/12/doctors-warn-covid-will-become-endemic-and-people-need-to-learn-to-live-with-it.html?recirc=taboolainternal
In this article it is pointed out that unfortunately "Some low-income countries have not received a single dose of vaccine to protect people most at risk from the coronavirus."
Dear Ijaz Durrani, please go through the link below for good insight.
Preprint The effectiveness of the first dose of BNT162 b 2 vaccine in...
Dear Ijaz Durrani please also see this potentially useful article entitled
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
Article Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by ...
According to the authors "Here, we tested SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 40 participants who were vaccinated in a previously reported trial with the mRNA-based COVID-19 vaccine BNT162b2. The immune sera had slightly reduced but overall largely preserved neutralizing titers against the B.1.1.7 lineage pseudovirus. These data indicate that the B.1.1.7 lineage will not escape BNT162b2-mediated protection."
- Badges
- Science topic
- Similar topics
- Medicine
- Disease
- Infectious Diseases
- Immunization